Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6167962 | 0.98 | CYP1A2 (0.52) | CYP1A2CYP2D6ALDH1A1POLBNPSR1 | |
| SCHEMBL25579654 | 0.82 | TAAR1 (0.44) | TAAR1SMN1; SMN2HTR2CHTR2BMEN1 | |
| SCHEMBL14540142 | 0.81 | CYP1A2 (0.37) | CYP1A2CYP2D6ALDH1A1POLBNPSR1 | |
| SCHEMBL8239748 | 0.81 | TAAR1 (0.50) | TAAR1SMN1; SMN2HTR2AHTR2CKMT2A | |
| SCHEMBL6161969 | 0.81 | TAAR1 (0.58) | TAAR1 | |
| SCHEMBL8118171 | 0.81 | OPRM1 (0.47) | TAAR1SMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL8067779 | 0.81 | TAAR1 (0.42) | TAAR1SMN1; SMN2HTR2AHTR2CHTR2B | |
| SCHEMBL1524562 | 0.79 | MAPT (0.44) | NPSR1TAAR1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL8446859 | 0.79 | KDM1A (0.44) | CYP2D6ALDH1A1NPSR1TAAR1MAPT | |
| SCHEMBL11391883 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP2D6ALDH1A1POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA | 2020-07-23 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-10438688-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-10-08 | — | — | US | disclosed |
| US-10438688-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2019-10-08 | — | — | US | disclosed |
| WO-2019005883-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2019-01-03 | — | — | WO | disclosed |
| CN-103130745-A | Diaryl-piperazines compound and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2013-06-05 | — | — | CN | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| CN-1056842-C | Amino acid derivative having anti CCK activity | TOBISHI PHARMACEUTICAL CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| WO-1999031063-A1 | NEW PIPERAZINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| EP-0710661-B1 | Amino acid derivative having anti-CKK activity | TOBISHI PHARMACEUTICAL CO (JP) | 1999-03-31 | — | — | EP | disclosed |
| US-5716958-A | GASTROINTESTINAL DISORDERS; INHIBITORY ACTIVITY ON CHOLECYSTOKININ | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0710661-A1 | Amino acid derivative having anti-CKK activity | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| CN-1121515-A | Amino acid derivative having anti CCK activity | TOBISHI PHARMACEUTICAL CO (JP) | 1996-05-01 | — | — | CN | disclosed |
| EP-0535152-B1 | Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylene and piperazine compounds as PAF antagonists and compositions thereof. | SCHERING CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| US-5422351-A | Antiallergens; antiinflammatory agents | SCHERING CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0535152-A1 | BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS. | SCHERING CORP (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992000293-A1 | BIS-BENZO OR BENZOPYRIDO CYCLO HEPTA PIPERIDENE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | CYP11B2, NQO1, CYP11B1 | CYP1A2 86/4885CYP2D6 188/4885ALDH1A1 274/4885 |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | CYP1A2 4271/4885CYP2D6 3836/4885ALDH1A1 1721/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | CYP1A2 4271/4885CYP2D6 3836/4885ALDH1A1 1721/4885 |
| US-10438688-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | CYP1A2 4271/4885CYP2D6 3836/4885ALDH1A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.